Larkspur Biosciences’ cover photo
Larkspur Biosciences

Larkspur Biosciences

Biotechnology Research

Cambridge, MA 1,859 followers

Destroying tumors by targeting cancer cell fitness.

About us

Targeting enzymes that control cancer cell state and fitness make cancer cells susceptible to intrinsic and immune-mediated killing but drugging these pathways has been limited by poor tractability. Larkspur develops small molecules that overcome these limitations, decreasing cancer cell fitness and sensitizing them to intrinsic and immune-driven mechanisms of killing. LarkX, our proprietary machine-learning-enabled gene signature platform, identifies pathways with cancer cell-intrinsic adaptations that drive immune evasion. This identifies novel targets that mediate pathological cell-to-cell communication. Larkspur’s clinical development focuses on biomarker-driven cancer patient cohorts to achieve early proof-of-concept. Our first-in-class pipeline programs are initially focused on colorectal cancer (CRC), with opportunities to expand to multiple cancers. We believe that transformational discoveries are found at the interface between disciplines. With a proven track record of drug discovery and development, our team is passionate about solving hard problems and driven to deliver new medicines to cancer patients with significant unmet needs. At Larkspur, we grow together, building a culture that highly values joy, trust, and courage.

Website
https://larkspur.bio/
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Cambridge, MA
Type
Privately Held
Founded
2020
Specialties
Oncology, Immunotherapy, and Precision Medicine

Locations

Employees at Larkspur Biosciences

Updates

Similar pages

Browse jobs

Funding